Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Down 3.2%

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) were down 3.2% during trading on Friday . The stock traded as low as $14.68 and last traded at $14.76. Approximately 90,412 shares changed hands during trading, a decline of 97% from the average daily volume of 2,831,862 shares. The stock had previously closed at $15.25.

Analyst Ratings Changes

Several analysts recently commented on CPRX shares. Roth Capital cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the stock from $10.00 to $15.50 in a report on Wednesday, August 24th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, August 11th. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, August 11th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 8th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.81.

Catalyst Pharmaceuticals Stock Down 3.1 %

The stock has a market cap of $1.52 billion, a P/E ratio of 28.96 and a beta of 1.31. The firm’s 50-day moving average is $11.48 and its two-hundred day moving average is $8.88.

Insider Activity at Catalyst Pharmaceuticals

In related news, CFO Alicia Grande sold 130,741 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $13.86, for a total transaction of $1,812,070.26. Following the transaction, the chief financial officer now owns 475,537 shares of the company’s stock, valued at $6,590,942.82. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $13.53, for a total value of $2,029,500.00. Following the transaction, the chief operating officer now owns 761,724 shares of the company’s stock, valued at $10,306,125.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Alicia Grande sold 130,741 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $13.86, for a total transaction of $1,812,070.26. Following the completion of the transaction, the chief financial officer now directly owns 475,537 shares in the company, valued at approximately $6,590,942.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 374,988 shares of company stock valued at $5,134,603. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. M&G Investment Management Ltd. raised its position in shares of Catalyst Pharmaceuticals by 5.3% in the second quarter. M&G Investment Management Ltd. now owns 228,278 shares of the biopharmaceutical company’s stock valued at $1,598,000 after purchasing an additional 11,514 shares during the period. Legal & General Group Plc increased its position in Catalyst Pharmaceuticals by 8.4% during the second quarter. Legal & General Group Plc now owns 37,751 shares of the biopharmaceutical company’s stock worth $265,000 after acquiring an additional 2,917 shares during the period. ExodusPoint Capital Management LP increased its position in Catalyst Pharmaceuticals by 837.9% during the second quarter. ExodusPoint Capital Management LP now owns 203,993 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 182,242 shares during the period. Goldman Sachs Group Inc. increased its position in Catalyst Pharmaceuticals by 73.2% during the second quarter. Goldman Sachs Group Inc. now owns 1,910,664 shares of the biopharmaceutical company’s stock worth $13,394,000 after acquiring an additional 807,303 shares during the period. Finally, AQR Capital Management LLC increased its position in Catalyst Pharmaceuticals by 17.9% during the second quarter. AQR Capital Management LLC now owns 487,541 shares of the biopharmaceutical company’s stock worth $3,418,000 after acquiring an additional 73,989 shares during the period. Institutional investors own 74.16% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Featured Stories

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.